TherapeuticsMD
TXMD
150 hedge funds and large institutions have $627M invested in TherapeuticsMD in 2019 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 45 increasing their positions, 39 reducing their positions, and 20 closing their positions.
28% more capital invested
Capital invested by funds: $489M → $627M (+$138M)
15% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 39
15% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 20
1% more funds holding
Funds holding: 148 → 150 (+2)
0.13% less ownership
Funds ownership: 1.57% → 1.43% (-0.13%)
14% less call options, than puts
Call options by funds: $4.87M | Put options by funds: $5.69M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$2.6M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.47M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$2.01M |
| 4 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$1.82M |
| 5 |
BCA
Bay Colony Advisors
Concord,
Massachusetts
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$18.8M |
| 2 |
Bank of New York Mellon
New York
|
-$16M |
| 3 |
SG Americas Securities
New York
|
-$6.88M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$4.96M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$4.04M |
TXMD Hedge Fund Activity: Q3 2019 in Review
150 of the 4,573 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q3 2019, worth a combined $627M — up 28% from $489M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new TXMD positions and 20 closed out — a net gain of 3 holders — while 45 added to existing stakes and 39 trimmed.
The largest buyer was Northern Trust, adding an estimated $2.6M. The largest seller was T. Rowe Price Associates, cutting an estimated $18.8M.
- 150 institutional investors held TherapeuticsMD (TXMD) as of Q3 2019, up from 148 in Q2 2019.
- Funds reported $627M of TherapeuticsMD stock for Q3 2019, up 28% quarter-over-quarter.
- 23 funds opened new TherapeuticsMD positions in Q3 2019 and 20 closed out, a net change of +3 holders.
- The largest TherapeuticsMD buyer in Q3 2019 was Northern Trust, an estimated $2.6M added.
- The largest TherapeuticsMD seller in Q3 2019 was T. Rowe Price Associates, an estimated $18.8M sold.
Based on aggregated 13F filings for Q3 2019.